贝那普利联合美托洛尔治疗慢性心力衰竭的180例疗效观察

The Clinical Efficacy of Benazepril Combined with Metoprolol of 180 Cases for Chronic Heart Failure

目的探讨贝那普利联合美托洛尔治疗慢性心力衰竭的有效性和安全性。方法选取2010年12月—2012年12月期间就诊于该院的慢性心力衰竭患者180例进行回顾性分析并随机分为2组,每组90例。其中,对照组在常规方法(如强心、利尿、扩血管等)治疗的基础上,给予贝那普利治疗,而观察组则在对照组的基础上联合美托洛尔进行治疗。观察用药前后两组患者心功能的改善情况,比较2种治疗方法的临床疗效和不良反应的发生情况。结果治疗后,观察组患者的心功能明显改善,总有效率为95.56%,不良反应率为12.22%,而对照组总有效率则为83.33%,不良反应率为11.11%,可见观察组的有效性明显优于对照组,经分析,差异有统计学意义(P<0.05),而不良反应的发生差异无统计学意义(P>0.05)。结论贝那普利联合美托洛尔治疗能够显著改善慢性心力衰竭患者的临床症状,其疗效确切,安全性高,值得在临床上推广使用。

Objective Explore the efficacy and safety of benazepril combined with metoprolol for patients with chronic heart fail- ure. Methods Retrospectively analyzed the 180 chronic heart failure patients in our hospital from December 2010 to December 2012. Randomly divided into two groups and 90 cases in each group.The control group were treated with benazepril on the basis of conventional treatment （such as cardiac, diuretic, vasodilator, etc.）, while the observation group were treated with metoprolol on the basis of the control group. Observed the improvements of heart function.Compared the clinical efficacy and adverse events of two groups. Results After treatment, the heart function of the observation group was significantly improved. The total effective rate of the observation group is 95.56% and the adverse reaction rate was 12.22%, while the control group is 83.33% and 11.11%. Visi- ble, the efficacy of the observation group was significantly higher than the control group which has statistically significant differ- ences（P〈0.05）. But there were no significant differences of the adverse reaction rate （P〉0.05）. Conclusion The treatment of be- nazepril combined with metoprolol can significantly improved the heart function. It is effective and safe which is worth to use in clinical practice.